{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:24:16Z","timestamp":1775201056579,"version":"3.50.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41571-022-00722-1","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T15:12:31Z","timestamp":1673277151000},"page":"178-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":295,"title":["The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-0033","authenticated-orcid":false,"given":"Sofia","family":"Mensurado","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-8699","authenticated-orcid":false,"given":"Rafael","family":"Blanco-Dom\u00ednguez","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9302","authenticated-orcid":false,"given":"Bruno","family":"Silva-Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"722_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0092-8674(85)90140-0","volume":"40","author":"AC Hayday","year":"1985","unstructured":"Hayday, A. C. et al. Structure, organization, and somatic rearrangement of T cell gamma genes. Cell 40, 259\u2013269 (1985).","journal-title":"Cell"},{"key":"722_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/322179a0","volume":"322","author":"I Bank","year":"1986","unstructured":"Bank, I. et al. A functional T3 molecule associated with a novel heterodimer on the surface of immature human thymocytes. Nature 322, 179\u2013181 (1986).","journal-title":"Nature"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/322145a0","volume":"322","author":"MB Brenner","year":"1986","unstructured":"Brenner, M. B. et al. Identification of a putative second T-cell receptor. Nature 322, 145\u2013149 (1986).","journal-title":"Nature"},{"key":"722_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/330572a0","volume":"330","author":"W Born","year":"1987","unstructured":"Born, W. et al. Peptide sequences of T-cell receptor \u03b4 and \u03b3 chains are identical to predicted X and \u03b3 proteins. Nature 330, 572\u2013574 (1987).","journal-title":"Nature"},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology. Nat. Rev. Immunol. 13, 88\u2013100 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"722_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","volume":"21","author":"JC Ribot","year":"2021","unstructured":"Ribot, J. C., Lopes, N. & Silva-Santos, B. \u03b3\u03b4 T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21, 221\u2013232 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos, B., Mensurado, S. & Coffelt, S. B. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392\u2013404 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen, Z., Prinz, I., D\u00e9chanet-Merville, J., Silva-Santos, B. & Kuball, J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169\u2013184 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41587-022-01363-6","volume":"40","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. Unconventional \u03b3\u03b4 T cells \u2018the new black\u2019 in cancer therapy. Nat. Biotechnol. 40, 805\u2013808 (2022).","journal-title":"Nat. Biotechnol."},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"915837","DOI":"10.3389\/fimmu.2022.915837","volume":"13","author":"J Saura-Esteller","year":"2022","unstructured":"Saura-Esteller, J. et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front. Immunol. 13, 915837 (2022).","journal-title":"Front. Immunol."},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz, D., Serrano, R., Kouakanou, L., Peters, C. & Kalyan, S. Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us. Cell. Mol. Immunol. 17, 925\u2013939 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.4049\/jimmunol.151.9.4465","volume":"151","author":"M Bigby","year":"1993","unstructured":"Bigby, M. et al. Most gamma delta T cells develop normally in the absence of MHC class II molecules. J. Immunol. 151, 4465\u20134475 (1993).","journal-title":"J. Immunol."},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41423-020-0503-y","volume":"17","author":"M Deseke","year":"2020","unstructured":"Deseke, M. & Prinz, I. Ligand recognition by the \u03b3\u03b4 TCR and discrimination between homeostasis and stress conditions. Cell. Mol. Immunol. 17, 914\u2013924 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. \u03b3\u03b4 T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"722_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4049\/jimmunol.165.2.931","volume":"165","author":"Y Mokuno","year":"2000","unstructured":"Mokuno, Y. et al. Expression of toll-like receptor 2 on \u03b3\u03b4 T cells bearing invariant V\u03b36\/V\u03b41 induced by Escherichia coli infection in mice. J. Immunol. 165, 931\u2013940 (2000).","journal-title":"J. Immunol."},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.immuni.2013.06.015","volume":"39","author":"BS Sheridan","year":"2013","unstructured":"Sheridan, B. S. et al. \u03b3\u03b4 T cells exhibit multifunctional and protective memory in intestinal tissues. Immunity 39, 184\u2013195 (2013).","journal-title":"Immunity"},{"key":"722_CR17","first-page":"595","volume":"6","author":"MP Lefranc","year":"2011","unstructured":"Lefranc, M. P. IMGT, the international ImMunoGeneTics information system. Cold Spring Harb. Protoc. 6, 595\u2013603 (2011).","journal-title":"Cold Spring Harb. Protoc."},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4161\/onci.23304","volume":"2","author":"D Kabelitz","year":"2013","unstructured":"Kabelitz, D., Kalyan, S., Oberg, H. H. & Wesch, D. Human V\u03b42 versus non-V\u03b42 \u03b3\u03b4 T cells in antitumor immunity. Oncoimmunology 2, 37\u201341 (2013).","journal-title":"Oncoimmunology"},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1523-1747.2001.01250.x","volume":"116","author":"W Holtmeier","year":"2001","unstructured":"Holtmeier, W. et al. The TCR \u03b4 repertoire in normal human skin is restricted and distinct from the TCR \u03b4 repertoire in the peripheral blood. J. Invest. Dermatol. 116, 275\u2013280 (2001).","journal-title":"J. Invest. Dermatol."},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/cmi.2012.44","volume":"10","author":"S Kalyan","year":"2013","unstructured":"Kalyan, S. & Kabelitz, D. Defining the nature of human \u03b3\u03b4 T cells: a biographical sketch of the highly empathetic. Cell. Mol. Immunol. 10, 21\u201329 (2013).","journal-title":"Cell. Mol. Immunol."},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1084\/jem.172.3.847","volume":"172","author":"MS Krangel","year":"1990","unstructured":"Krangel, M. S., Yssel, H., Brocklehurst, C. & Spits, H. A distinct wave of human T cell receptor \u03b3\/\u03b4 lymphocytes in the early fetal thymus: evidence for controlled gene rearrangement and cytokine production. J. Exp. Med. 172, 847\u2013859 (1990).","journal-title":"J. Exp. Med."},{"key":"722_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3389\/fimmu.2018.01501","volume":"9","author":"CR Willcox","year":"2018","unstructured":"Willcox, C. R., Davey, M. S. & Willcox, B. E. Development and selection of the human V\u03b39V\u03b42+ T-cell repertoire. Front. Immunol. 9, 1501 (2018).","journal-title":"Front. Immunol."},{"key":"722_CR23","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.4049\/jimmunol.157.7.2873","volume":"157","author":"LD McVay","year":"1996","unstructured":"McVay, L. D. & Carding, S. R. Extrathymic origin of human gamma delta T cells during fetal development. J. Immunol. 157, 2873\u20132882 (1996).","journal-title":"J. Immunol."},{"key":"722_CR24","doi-asserted-by":"publisher","first-page":"90ra61","DOI":"10.1126\/scitranslmed.3002536","volume":"3","author":"AM Sherwood","year":"2011","unstructured":"Sherwood, A. M. et al. Deep sequencing of the human TCR\u03b3 and TCR\u03b2 repertoires suggests that TCR\u03b2 rearranges after \u03b1\u03b2 and \u03b3\u03b4 T cell commitment. Sci. Transl. Med. 3, 90ra61 (2011).","journal-title":"Sci. Transl. Med."},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.4049\/jimmunol.1000231","volume":"184","author":"H Wang","year":"2010","unstructured":"Wang, H., Fang, Z. & Morita, C. T. V\u03b32V\u03b42 T cell receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J. Immunol. 184, 6209\u20136222 (2010).","journal-title":"J. Immunol."},{"key":"722_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-5793(01)03191-X","volume":"509","author":"M Hintz","year":"2001","unstructured":"Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human \u03b3\u03b4 T cells in Escherichia coli. FEBS Lett. 509, 317\u2013322 (2001).","journal-title":"FEBS Lett."},{"key":"722_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","volume":"375","author":"Y Tanaka","year":"1995","unstructured":"Tanaka, Y., Morita, C. T., Nieves, E., Brenner, M. B. & Bloom, B. R. Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4 T cells. Nature 375, 155\u2013158 (1995).","journal-title":"Nature"},{"key":"722_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober, H. J. et al. Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163\u2013168 (2003).","journal-title":"J. Exp. Med."},{"key":"722_CR29","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","volume":"71","author":"I Benza\u00efd","year":"2011","unstructured":"Benza\u00efd, I. et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V\u03b39V\u03b42 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 71, 4562\u20134572 (2011).","journal-title":"Cancer Res."},{"key":"722_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bbrc.2015.05.118","volume":"463","author":"E Ashihara","year":"2015","unstructured":"Ashihara, E. et al. Isopentenyl pyrophosphate secreted from zoledronate-stimulated myeloma cells, activates the chemotaxis of \u03b3\u03b4T cells. Biochem. Biophys. Res. Commun. 463, 650\u2013655 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"722_CR31","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly, C. et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset. Blood 120, 2269\u20132279 (2012).","journal-title":"Blood"},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","volume":"40","author":"A Sandstrom","year":"2014","unstructured":"Sandstrom, A. et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42T cells. Immunity 40, 490\u2013500 (2014).","journal-title":"Immunity"},{"key":"722_CR33","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.4049\/jimmunol.1601910","volume":"198","author":"C-M Peign\u00e9","year":"2017","unstructured":"Peign\u00e9, C.-M. et al. The juxtamembrane domain of butyrophilin BTN3A1 controls phosphoantigen-mediated activation of human V\u03b39V\u03b42 T cells. J. Immunol. 198, 4228\u20134234 (2017).","journal-title":"J. Immunol."},{"key":"722_CR34","doi-asserted-by":"publisher","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","volume":"114","author":"S Gu","year":"2017","unstructured":"Gu, S. et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V\u03b39V\u03b42 T cell activation. Proc. Natl Acad. Sci. USA 114, E7311\u2013E7320 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.02.016","volume":"50","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated V\u03b39V\u03b42 T cell activation. Immunity 50, 1043\u20131053.e5 (2019).","journal-title":"Immunity"},{"key":"722_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.chembiol.2022.01.004","volume":"29","author":"C-HC Hsiao","year":"2022","unstructured":"Hsiao, C.-H. C., Nguyen, K., Jin, Y., Vinogradova, O. & Wiemer, A. J. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex. Cell Chem. Biol. 29, 985\u2013995.e5 (2022).","journal-title":"Cell Chem. Biol."},{"key":"722_CR37","doi-asserted-by":"publisher","first-page":"eaay5516","DOI":"10.1126\/science.aay5516","volume":"367","author":"M Rigau","year":"2020","unstructured":"Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells. Science 367, eaay5516 (2020).","journal-title":"Science"},{"key":"722_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/157340607779317544","volume":"3","author":"Y Tanaka","year":"2007","unstructured":"Tanaka, Y. et al. Synthesis of pyrophosphate-containing compounds that stimulate V\u03b32V\u03b42 T cells: application to cancer immunotherapy. Med. Chem. 3, 85\u201399 (2007).","journal-title":"Med. Chem."},{"key":"722_CR39","first-page":"1471","volume":"19","author":"RN Wang","year":"2019","unstructured":"Wang, R. N. et al. Optimized protocols for \u03b3\u03b4 T cell expansion and lentiviral transduction. Mol. Med. Rep. 19, 1471\u20131480 (2019).","journal-title":"Mol. Med. Rep."},{"key":"722_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06754.x","volume":"139","author":"M Burjanadz\u00e9","year":"2007","unstructured":"Burjanadz\u00e9, M. et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by phosphostim and IL-2 in patients with multiple myeloma. Br. J. Haematol. 139, 206\u2013216 (2007).","journal-title":"Br. J. Haematol."},{"key":"722_CR41","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fimmu.2018.00800","volume":"9","author":"T Hoeres","year":"2018","unstructured":"Hoeres, T., Smetak, M., Pretscher, D. & Wilhelm, M. Improving the efficiency of V\u03b39V\u03b42 T-cell immunotherapy in cancer. Front. Immunol. 9, 800 (2018).","journal-title":"Front. Immunol."},{"key":"722_CR42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/eji.201646818","volume":"47","author":"L Starick","year":"2017","unstructured":"Starick, L. et al. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates V\u03b39V\u03b42 TCR clonotypes and interferes with phosphoantigen activation. Eur. J. Immunol. 47, 982\u2013992 (2017).","journal-title":"Eur. J. Immunol."},{"key":"722_CR43","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1126\/science.aay2767","volume":"369","author":"KK Payne","year":"2020","unstructured":"Payne, K. K. et al. BTN3A1 governs antitumor responses by coordinating \u03b1\u03b2 and \u03b3\u03b4 T cells. Science 369, 942\u2013949 (2020).","journal-title":"Science"},{"key":"722_CR44","doi-asserted-by":"publisher","first-page":"eabj0835","DOI":"10.1126\/scitranslmed.abj0835","volume":"13","author":"A De Gassart","year":"2021","unstructured":"De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835 (2021).","journal-title":"Sci. Transl. Med."},{"key":"722_CR45","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41590-018-0253-5","volume":"19","author":"D Melandri","year":"2018","unstructured":"Melandri, D. et al. The \u03b3\u03b4TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat. Immunol. 19, 1352\u20131365 (2018).","journal-title":"Nat. Immunol."},{"key":"722_CR46","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.4049\/jimmunol.175.4.2144","volume":"175","author":"B Rincon-Orozco","year":"2005","unstructured":"Rincon-Orozco, B. et al. Activation of V\u03b39V\u03b42 T cells by NKG2D. J. Immunol. 175, 2144\u20132151 (2005).","journal-title":"J. Immunol."},{"key":"722_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","volume":"66","author":"P Wrobel","year":"2007","unstructured":"Wrobel, P. et al. Lysis of a broad range of epithelial tumour cells by human \u03b3\u03b4 T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand. J. Immunol. 66, 320\u2013328 (2007).","journal-title":"Scand. J. Immunol."},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/eji.200838409","volume":"39","author":"O Toutirais","year":"2009","unstructured":"Toutirais, O. et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by V\u03b39V\u03b42 T cells. Eur. J. Immunol. 39, 1361\u20131368 (2009).","journal-title":"Eur. J. Immunol."},{"key":"722_CR49","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","volume":"104","author":"DF Angelini","year":"2004","unstructured":"Angelini, D. F. et al. Fc\u03b3RIII discriminates between 2 subsets of V\u03b39V\u03b42 effector cells with different responses and activation pathways. Blood 104, 1801\u20131807 (2004).","journal-title":"Blood"},{"key":"722_CR50","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","volume":"113","author":"J Gertner-Dardenne","year":"2009","unstructured":"Gertner-Dardenne, J. et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113, 4875\u20134884 (2009).","journal-title":"Blood"},{"key":"722_CR51","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/ijc.23365","volume":"122","author":"H Tokuyama","year":"2008","unstructured":"Tokuyama, H. et al. V\u03b39V\u03b42 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs\u2013rituximab and trastuzumab. Int. J. Cancer 122, 2526\u20132534 (2008).","journal-title":"Int. J. Cancer"},{"key":"722_CR52","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.0810059106","volume":"106","author":"M Brandes","year":"2009","unstructured":"Brandes, M. et al. Cross-presenting human \u03b3\u03b4 T cells induce robust CD8+ \u03b1\u03b2 T cell responses. Proc. Natl Acad. Sci. USA 106, 2307\u20132312 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri797","volume":"2","author":"SR Carding","year":"2002","unstructured":"Carding, S. R. & Egan, P. J. \u03b3\u03b4 T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336\u2013345 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"722_CR54","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2008-01-136713","volume":"112","author":"V Pitard","year":"2008","unstructured":"Pitard, V. et al. Long-term expansion of effector\/memory V\u03b42\u2212 \u03b3\u03b4 T cells is a specific blood signature of CMV infection. Blood 112, 1317\u20131324 (2008).","journal-title":"Blood"},{"key":"722_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fimmu.2017.00105","volume":"8","author":"C Khairallah","year":"2017","unstructured":"Khairallah, C., D\u00e9chanet-Merville, J. & Capone, M. \u03b3\u03b4 T cell-mediated immunity to cytomegalovirus infection. Front. Immunol. 8, 105 (2017).","journal-title":"Front. Immunol."},{"key":"722_CR56","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/bmt.2013.75","volume":"48","author":"L Farnault","year":"2013","unstructured":"Farnault, L. et al. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation. Bone Marrow Transpl. 48, 1478\u20131479 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"722_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2249.2007.03388.x","volume":"149","author":"N Fujishima","year":"2007","unstructured":"Fujishima, N. et al. Skewed T cell receptor repertoire of V\u03b41+ \u03b3\u03b4 T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin. Exp. Immunol. 149, 70\u201379 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"722_CR58","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ni.3686","volume":"18","author":"S Ravens","year":"2017","unstructured":"Ravens, S. et al. Human \u03b3\u03b4 T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat. Immunol. 18, 393\u2013401 (2017).","journal-title":"Nat. Immunol."},{"key":"722_CR59","doi-asserted-by":"publisher","first-page":"14760","DOI":"10.1038\/ncomms14760","volume":"8","author":"MS Davey","year":"2017","unstructured":"Davey, M. S. et al. Clonal selection in the human V\u03b41 T cell repertoire indicates \u03b3\u03b4 TCR-dependent adaptive immune surveillance. Nat. Commun. 8, 14760 (2017).","journal-title":"Nat. Commun."},{"key":"722_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41597-019-0118-2","volume":"6","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B., Ravens, S. & Silva-Santos, B. High-throughput analysis of the human thymic V\u03b41+ T cell receptor repertoire. Sci. Data 6, 115 (2019).","journal-title":"Sci. Data"},{"key":"722_CR61","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1084\/jem.191.6.937","volume":"191","author":"FM Spada","year":"2000","unstructured":"Spada, F. M. et al. Self-recognition of CD1 by \u03b3\/\u03b4 T cells: implications for innate immunity. J. Exp. Med. 191, 937\u2013948 (2000).","journal-title":"J. Exp. Med."},{"key":"722_CR62","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ni.2713","volume":"14","author":"AP Uldrich","year":"2013","unstructured":"Uldrich, A. P. et al. CD1d-lipid antigen recognition by the \u03b3\u03b4 TCR. Nat. Immunol. 14, 1137\u20131145 (2013).","journal-title":"Nat. Immunol."},{"key":"722_CR63","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2013.11.001","volume":"39","author":"AM Luoma","year":"2013","unstructured":"Luoma, A. M. et al. Crystal structure of V\u03b41T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human \u03b3\u03b4 T cells. Immunity 39, 1032\u20131042 (2013).","journal-title":"Immunity"},{"key":"722_CR64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-lnducible MICA. Science 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"722_CR65","doi-asserted-by":"publisher","first-page":"9172","DOI":"10.1158\/0008-5472.CAN-04-2417","volume":"64","author":"A Poggi","year":"2004","unstructured":"Poggi, A. et al. V\u03b41 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 64, 9172\u20139179 (2004).","journal-title":"Cancer Res."},{"key":"722_CR66","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","volume":"14","author":"A Knight","year":"2012","unstructured":"Knight, A., MacKinnon, S. & Lowdell, M. W. Human V\u03b41 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14, 1110\u20131118 (2012).","journal-title":"Cytotherapy"},{"key":"722_CR67","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof-of-concept. Clin. Cancer Res. 22, 5795\u20135804 (2016).","journal-title":"Clin. Cancer Res."},{"key":"722_CR68","volume":"4","author":"J Mikulak","year":"2019","unstructured":"Mikulak, J. et al. NKp46-expressing human gut-resident intraepithelial V\u03b41 T cell subpopulation exhibits high antitumor activity against colorectal cancer. J. Clin. Invest. 4, e125884 (2019).","journal-title":"J. Clin. Invest."},{"key":"722_CR69","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","volume":"118","author":"DV Correia","year":"2011","unstructured":"Correia, D. V. et al. Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992\u20131001 (2011).","journal-title":"Blood"},{"key":"722_CR70","doi-asserted-by":"publisher","unstructured":"De Vries, N. L. et al. \u03b3\u03b4 T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects. Preprint at\u00a0https:\/\/doi.org\/10.1101\/2021.10.14.464229 (2021).","DOI":"10.1101\/2021.10.14.464229"},{"key":"722_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1371\/journal.pone.0076008","volume":"8","author":"MR Dunne","year":"2013","unstructured":"Dunne, M. R. et al. Persistent changes in circulating and intestinal \u03b3\u03b4 T cell subsets, invariant natural killer T cells and mucosal-associated invariant T cells in children and adults with coeliac disease. PLoS ONE 8, 2\u201311 (2013).","journal-title":"PLoS ONE"},{"key":"722_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clim.2004.05.003","volume":"113","author":"T Kenna","year":"2004","unstructured":"Kenna, T. et al. Distinct subpopulations of \u03b3\u03b4 T cells are present in normal and tumor-bearing human liver. Clin. Immunol. 113, 56\u201363 (2004).","journal-title":"Clin. Immunol."},{"key":"722_CR73","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1172\/JCI5409","volume":"103","author":"J D\u00e9chanet","year":"1999","unstructured":"D\u00e9chanet, J. et al. Implication of \u03b3\u03b4 T cells in the human immune response to cytomegalovirus. J. Clin. Invest. 103, 1437\u20131449 (1999).","journal-title":"J. Clin. Invest."},{"key":"722_CR74","first-page":"86","volume":"49","author":"J Bartkowiak","year":"2002","unstructured":"Bartkowiak, J., Kulczyck-Wojdala, D., Blonski, J. Z. & Robak, T. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma 49, 86\u201390 (2002).","journal-title":"Neoplasma"},{"key":"722_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4049\/jimmunol.1300121","volume":"191","author":"BA Mangan","year":"2013","unstructured":"Mangan, B. A. et al. Cutting edge: CD1d restriction and Th1\/Th2\/Th17 cytokine secretion by human V\u03b43 T cells. J. Immunol. 191, 30\u201334 (2013).","journal-title":"J. Immunol."},{"key":"722_CR76","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1073\/pnas.1621052114","volume":"114","author":"R Marlin","year":"2017","unstructured":"Marlin, R. et al. Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2. Proc. Natl Acad. Sci. USA 114, 3163\u20133168 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR77","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1126\/science.aav3900","volume":"366","author":"J Le Nours","year":"2019","unstructured":"Le Nours, J. et al. A class of \u03b3\u03b4 T cell receptors recognize the underside of the antigen-presenting molecule MR1. Science 366, 1522\u20131527 (2019).","journal-title":"Science"},{"key":"722_CR78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110288118","volume":"118","author":"MT Rice","year":"2021","unstructured":"Rice, M. T. et al. Recognition of the antigen-presenting molecule MR1 by a V\u03b43+ \u03b3\u03b4 T cell receptor. Proc. Natl Acad. Sci. USA 118, e2110288118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR79","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","volume":"38","author":"G Chitadze","year":"2017","unstructured":"Chitadze, G., Oberg, H. H., Wesch, D. & Kabelitz, D. The ambiguous role of \u03b3\u03b4 T lymphocytes in antitumor immunity. Trends Immunol. 38, 668\u2013678 (2017).","journal-title":"Trends Immunol."},{"key":"722_CR80","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"W Foulkes","year":"2010","unstructured":"Foulkes, W., Smith, I. & Reis-Filho, J. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"722_CR81","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.abj8695","volume":"377","author":"BS Reis","year":"2022","unstructured":"Reis, B. S. et al. TCR-V\u03b3\u03b4 usage distinguishes protumor from antitumor intestinal \u03b3\u03b4 T cell subsets. Science 377, 276\u2013284 (2022).","journal-title":"Science"},{"key":"722_CR82","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.trecan.2022.08.006","volume":"8","author":"S Mensurado","year":"2022","unstructured":"Mensurado, S. & Silva-Santos, B. Battle of the \u03b3\u03b4 T cell subsets in the gut. Trends Cancer 8, 881\u2013883 (2022).","journal-title":"Trends Cancer"},{"key":"722_CR83","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/ni.3726","volume":"18","author":"PH Papotto","year":"2017","unstructured":"Papotto, P. H., Ribot, J. C. & Silva-Santos, B. IL-17+ \u03b3\u03b4 T cells as kick-starters of inflammation. Nat. Immunol. 18, 604\u2013611 (2017).","journal-title":"Nat. Immunol."},{"key":"722_CR84","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"722_CR85","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/0008-5472.CAN-14-3228","volume":"75","author":"M Rei","year":"2015","unstructured":"Rei, M., Pennington, D. J. & Silva-Santos, B. The emerging protumor role of \u03b3\u03b4 T lymphocytes: implications for cancer immunotherapy. Cancer Res 75, 798\u2013802 (2015).","journal-title":"Cancer Res"},{"key":"722_CR86","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","volume":"192","author":"JC Ribot","year":"2014","unstructured":"Ribot, J. C., Silva-Santos, B., Correia, D. V., Sousa, A. E. & Ribeiro, S. T. Human \u03b3\u03b4 thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling. J. Immunol. 192, 2237\u20132243 (2014).","journal-title":"J. Immunol."},{"key":"722_CR87","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1126\/science.1063916","volume":"294","author":"M Girardi","year":"2001","unstructured":"Girardi, M. et al. Regulation of cutaneous malignancy by \u03b3\u03b4 T cells. Science 294, 605\u2013609 (2001).","journal-title":"Science"},{"key":"722_CR88","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1084\/jem.20030584","volume":"198","author":"Y Gao","year":"2003","unstructured":"Gao, Y. et al. \u03b3\u03b4 T cells provide an early source of interferon \u03b3 in tumor immunity. J. Exp. Med. 198, 433\u2013442 (2003).","journal-title":"J. Exp. Med."},{"key":"722_CR89","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1084\/jem.20031981","volume":"199","author":"SEA Street","year":"2004","unstructured":"Street, S. E. A. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and \u03b3\u03b4 T cells. J. Exp. Med. 199, 879\u2013884 (2004).","journal-title":"J. Exp. Med."},{"key":"722_CR90","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.180.9.6044","volume":"180","author":"Z Liu","year":"2008","unstructured":"Liu, Z. et al. Protective immunosurveillance and therapeutic antitumor activity of \u03b3\u03b4 T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180, 6044\u20136053 (2008).","journal-title":"J. Immunol."},{"key":"722_CR91","first-page":"384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann, V. et al. Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Hematology 96, 384\u2013392 (2000).","journal-title":"Hematology"},{"key":"722_CR92","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","volume":"174","author":"E Viey","year":"2005","unstructured":"Viey, E. et al. Phosphostim-activated \u03b3\u03b4 T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338\u20131347 (2005).","journal-title":"J. Immunol."},{"key":"722_CR93","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","volume":"56","author":"SR Mattarollo","year":"2007","unstructured":"Mattarollo, S. R., Kenna, T., Nieda, M. & Nicol, A. J. Chemotherapy and zoledronate sensitize solid tumour cells to V\u03b39V\u03b42 T cell cytotoxicity. Cancer Immunol. Immunother. 56, 1285\u20131297 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"722_CR94","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro, M. et al. V\u03b39V\u03b42 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184, 3260\u20133268 (2010).","journal-title":"J. Immunol."},{"key":"722_CR95","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","volume":"9","author":"AE Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es, A. E., Di Lorenzo, B. & Silva-Santos, B. Molecular determinants of target cell recognition by human \u03b3\u03b4 T cells. Front. Immunol. 9, 929 (2018).","journal-title":"Front. Immunol."},{"key":"722_CR96","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-07-4912","volume":"14","author":"AAZ Alexander","year":"2008","unstructured":"Alexander, A. A. Z. et al. Isopentenyl pyrophosphate-activated CD56+ \u03b3\u03b4 T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14, 4232\u20134240 (2008).","journal-title":"Clin. Cancer Res."},{"key":"722_CR97","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.4049\/jimmunol.0804288","volume":"182","author":"M Todaro","year":"2009","unstructured":"Todaro, M. et al. Efficient killing of human colon cancer stem cells by \u03b3\u03b4 T lymphocytes. J. Immunol. 182, 7287\u20137296 (2009).","journal-title":"J. Immunol."},{"key":"722_CR98","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1002\/eji.201243150","volume":"43","author":"P Dokouhaki","year":"2013","unstructured":"Dokouhaki, P. et al. NKG2D regulates production of soluble TRAIL by ex vivo expanded human \u03b3\u03b4 T cells. Eur. J. Immunol. 43, 3175\u20133182 (2013).","journal-title":"Eur. J. Immunol."},{"key":"722_CR99","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","volume":"187","author":"A-H Capietto","year":"2011","unstructured":"Capietto, A.-H., Martinet, L. & Fournie, J.-J. Stimulated \u03b3\u03b4 T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J. Immunol. 187, 1031\u20131038 (2011).","journal-title":"J. Immunol."},{"key":"722_CR100","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-13-3464","volume":"20","author":"JPH Fisher","year":"2014","unstructured":"Fisher, J. P. H. et al. Neuroblastoma killing properties of V\u03b42 and V\u03b42-negative \u03b3\u03b4T cells following expansion by artificial antigen presenting cells. Clin. Cancer Res. 20, 5720\u20135732 (2014).","journal-title":"Clin. Cancer Res."},{"key":"722_CR101","first-page":"10","volume":"9","author":"J Riond","year":"2009","unstructured":"Riond, J., Rodriguez, S., Nicolau, M., Saati, T. & Gairin, J. E. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by \u03b3\u03b4 T and NK cells during the early steps of tumor growth. Cancer Immun. 9, 10 (2009).","journal-title":"Cancer Immun."},{"key":"722_CR102","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","volume":"116","author":"A Maniar","year":"2010","unstructured":"Maniar, A. et al. Human \u03b3\u03b4 T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116, 1726\u20131733 (2010).","journal-title":"Blood"},{"key":"722_CR103","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes, M., Willimann, K. & Moser, B. Professional antigen-presentation function by human \u03b3\u03b4 T cells. Science 309, 264\u2013268 (2005).","journal-title":"Science"},{"key":"722_CR104","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00262-011-1111-6","volume":"61","author":"B Altvater","year":"2012","unstructured":"Altvater, B., Pscherer, S., Landmeier, S. & Kailayangiri, S. Activated human \u03b3\u03b4 T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunol. Immunother. 61, 385\u2013396 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"722_CR105","doi-asserted-by":"publisher","first-page":"645131","DOI":"10.3389\/fimmu.2021.645131","volume":"12","author":"G Holmen Olofsson","year":"2021","unstructured":"Holmen Olofsson, G. et al. V\u03b39V\u03b42 T cells concurrently kill cancer cells and cross-present tumor antigens. Front. Immunol. 12, 645131 (2021).","journal-title":"Front. Immunol."},{"key":"722_CR106","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1102654","volume":"188","author":"N Himoudi","year":"2012","unstructured":"Himoudi, N. et al. Human \u03b3\u03b4 T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J. Immunol. 188, 1708\u20131716 (2012).","journal-title":"J. Immunol."},{"key":"722_CR107","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cells9030743","volume":"9","author":"F Rampoldi","year":"2020","unstructured":"Rampoldi, F., Ullrich, L. & Prinz, I. Revisiting the interaction of \u03b3\u03b4 T-cells and B-cells. Cells 9, 743 (2020).","journal-title":"Cells"},{"key":"722_CR108","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.183.5.2271","volume":"183","author":"L Wen","year":"1996","unstructured":"Wen, L., Peng, Q. & Kelsoe, G. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by \u201cnon \u03b1\/\u03b2\u201d T cells. J. Exp. Med. 183, 2271\u20132282 (1996).","journal-title":"J. Exp. Med."},{"key":"722_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05487-9","volume":"9","author":"RM Rezende","year":"2018","unstructured":"Rezende, R. M. et al. \u03b3\u03b4 T cells control humoral immune response by inducing T follicular helper cell differentiation. Nat. Commun. 9, 3151 (2018).","journal-title":"Nat. Commun."},{"key":"722_CR110","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.4049\/jimmunol.177.8.5290","volume":"177","author":"N Caccamo","year":"2006","unstructured":"Caccamo, N. et al. CXCR5 identifies a subset of V\u03b39V\u03b42 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J. Immunol. 177, 5290\u20135295 (2006).","journal-title":"J. Immunol."},{"key":"722_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/eji.201142017","volume":"42","author":"RR Bansal","year":"2012","unstructured":"Bansal, R. R., Mackay, C. R., Moser, B. & Eberl, M. IL-21 enhances the potential of human \u03b3\u03b4 T cells to provide B-cell help. Eur. J. Immunol. 42, 110\u2013119 (2012).","journal-title":"Eur. J. Immunol."},{"key":"722_CR112","doi-asserted-by":"publisher","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","volume":"111","author":"M Rei","year":"2014","unstructured":"Rei, M. et al. Murine CD27(\u2212) V\u03b36(+) \u03b3\u03b4 T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, E3562\u2013E3570 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR113","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"A Gentles","year":"2015","unstructured":"Gentles, A. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"722_CR114","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","volume":"40","author":"P Wu","year":"2014","unstructured":"Wu, P. et al. \u03b3\u03b4T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785\u2013800 (2014).","journal-title":"Immunity"},{"key":"722_CR115","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1347742","volume":"6","author":"S Meraviglia","year":"2017","unstructured":"Meraviglia, S. et al. Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).","journal-title":"Oncoimmunology"},{"key":"722_CR116","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/2326-6066.CIR-16-0348","volume":"5","author":"E Lo Presti","year":"2017","unstructured":"Lo Presti, E. et al. Squamous cell tumors recruit \u03b3\u03b4 T cells producing either IL17 or IFN\u03b3 depending on the tumor stage. Cancer Immunol. Res. 5, 397\u2013407 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"722_CR117","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12967-019-1897-0","volume":"17","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Distribution and functions of \u03b3\u03b4 T cells infiltrated in the ovarian cancer microenvironment. J. Transl. Med. 17, 144 (2019).","journal-title":"J. Transl. Med."},{"key":"722_CR118","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil, R. S. et al. IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int. J. Cancer 139, 869\u2013881 (2016).","journal-title":"Int. J. Cancer"},{"key":"722_CR119","doi-asserted-by":"crossref","first-page":"E9056","DOI":"10.1073\/pnas.1712883114","volume":"114","author":"D Van Hede","year":"2017","unstructured":"Van Hede, D. et al. Human papillomavirus oncoproteins induce a reorganization of epithelial-associated \u03b3\u03b4 T cells promoting tumor formation. Proc. Natl Acad. Sci. USA 114, E9056\u2013E9065 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"722_CR120","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1159\/000484390","volume":"43","author":"Z Hu","year":"2017","unstructured":"Hu, Z. et al. IL-17 activates the IL-6\/STAT3 signal pathway in the proliferation of hepatitis B virus-related hepatocellular carcinoma. Cell. Physiol. Biochem. 43, 2379\u20132390 (2017).","journal-title":"Cell. Physiol. Biochem."},{"key":"722_CR121","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3389\/fonc.2019.00546","volume":"9","author":"N Guo","year":"2019","unstructured":"Guo, N. et al. Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression. Front. Oncol. 9, 546 (2019).","journal-title":"Front. Oncol."},{"key":"722_CR122","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-15-0054","volume":"75","author":"L Benevides","year":"2015","unstructured":"Benevides, L. et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 75, 3788\u20133799 (2015).","journal-title":"Cancer Res."},{"key":"722_CR123","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/eji.200940157","volume":"40","author":"D Wakita","year":"2010","unstructured":"Wakita, D. et al. Tumor-infiltrating IL-17-producing \u03b3\u03b4 T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927\u20131937 (2010).","journal-title":"Eur. J. Immunol."},{"key":"722_CR124","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-15-0154","volume":"4","author":"P Kulig","year":"2016","unstructured":"Kulig, P. et al. IL17A-mediated endothelial breach promotes metastasis formation. Cancer Immunol. Res. 4, 26\u201332 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"722_CR125","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-13-2534","volume":"74","author":"S Ma","year":"2014","unstructured":"Ma, S. et al. IL-17A produced by \u03b3\u03b4 T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74, 1969\u20131982 (2014).","journal-title":"Cancer Res."},{"key":"722_CR126","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fimmu.2018.01271","volume":"9","author":"A Sacchi","year":"2018","unstructured":"Sacchi, A. et al. Myeloid-derived suppressor cells specifically suppress IFN-\u03b3 production and antitumor cytotoxic activity of V\u03b42 T cells. Front. Immunol. 9, 1271 (2018).","journal-title":"Front. Immunol."},{"key":"722_CR127","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41564-021-00948-2","volume":"6","author":"PH Papotto","year":"2021","unstructured":"Papotto, P. H., Yilmaz, B. & Silva-Santos, B. Crosstalk between \u03b3\u03b4 T cells and the microbiota. Nat. Microbiol. 6, 1110\u20131117 (2021).","journal-title":"Nat. Microbiol."},{"key":"722_CR128","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.040","volume":"176","author":"C Jin","year":"2019","unstructured":"Jin, C. et al. Commensal microbiota promote lung cancer development via \u03b3\u03b4 T cells. Cell 176, 998\u20131013.e16 (2019).","journal-title":"Cell"},{"key":"722_CR129","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/eji.201344195","volume":"44","author":"S Kalyan","year":"2014","unstructured":"Kalyan, S. & Kabelitz, D. When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. Eur. J. Immunol. 44, 627\u2013633 (2014).","journal-title":"Eur. J. Immunol."},{"key":"722_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2004990","volume":"16","author":"S Mensurado","year":"2018","unstructured":"Mensurado, S. et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ \u03b3\u03b4 T cells through induction of oxidative stress. PLoS Biol. 16, e2004990 (2018).","journal-title":"PLoS Biol."},{"key":"722_CR131","doi-asserted-by":"publisher","first-page":"699478","DOI":"10.3389\/fimmu.2021.699478","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. \u201c\u03b3\u03b4T cell-IL17A-neutrophil\u201d axis drives immunosuppression and confers breast cancer resistance to high-dose anti-VEGFR2 therapy. Front. Immunol. 12, 699478 (2021).","journal-title":"Front. Immunol."},{"key":"722_CR132","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2014.11.009","volume":"27","author":"MR Rutkowski","year":"2015","unstructured":"Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 27\u201340 (2015).","journal-title":"Cancer Cell"},{"key":"722_CR133","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","volume":"166","author":"D Daley","year":"2016","unstructured":"Daley, D. et al. \u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation. Cell 166, 1485\u20131499 (2016).","journal-title":"Cell"},{"key":"722_CR134","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.4049\/jimmunol.1101389","volume":"187","author":"J Hao","year":"2011","unstructured":"Hao, J. et al. Regulatory role of V\u03b31 \u03b3\u03b4 T cells in tumor immunity through IL-4 production. J. Immunol. 187, 4979\u20134986 (2011).","journal-title":"J. Immunol."},{"key":"722_CR135","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/cmi.2015.07","volume":"13","author":"Y Mao","year":"2016","unstructured":"Mao, Y. et al. A new effect of IL-4 on human \u03b3\u03b4 T cells: promoting regulatory V\u03b41 T cells via IL-10 production and inhibiting function of V\u03b42 T cells. Cell. Mol. Immunol. 13, 217\u2013228 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"722_CR136","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng, G. et al. Tumor-infiltrating \u03b3\u03b4 T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27, 334\u2013348 (2007).","journal-title":"Immunity"},{"key":"722_CR137","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.4049\/jimmunol.1202369","volume":"190","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Tumor-derived \u03b3\u03b4 regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 190, 2403\u20132414 (2013).","journal-title":"J. Immunol."},{"key":"722_CR138","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/JLB.3MA0420-278RR","volume":"107","author":"G Chabab","year":"2020","unstructured":"Chabab, G. et al. Identification of a regulatory V\u03b41 gamma delta T cell subpopulation expressing CD73 in human breast cancer. J. Leukoc. Biol. 107, 1057\u20131067 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"722_CR139","doi-asserted-by":"publisher","first-page":"eaax9364","DOI":"10.1126\/scitranslmed.aax9364","volume":"11","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. An innate-like V\u03b41+ \u03b3\u03b4 T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci. Transl. Med. 11, eaax9364 (2019).","journal-title":"Sci. Transl. Med."},{"key":"722_CR140","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.4049\/jimmunol.1201892","volume":"189","author":"C Ma","year":"2012","unstructured":"Ma, C. et al. Tumor-infiltrating \u03b3\u03b4 T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029\u20135036 (2012).","journal-title":"J. Immunol."},{"key":"722_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004579","volume":"10","author":"E Bruni","year":"2022","unstructured":"Bruni, E. et al. Intrahepatic CD69+V\u03b41 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J. Immunother. Cancer 10, e004579 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR142","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41467-022-29012-1","volume":"13","author":"N Zakeri","year":"2022","unstructured":"Zakeri, N. et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat. Commun. 13, 1372 (2022).","journal-title":"Nat. Commun."},{"key":"722_CR143","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1353858","volume":"6","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Tumor-infiltrating \u03b3\u03b4T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. Oncoimmunology 6, e1353858 (2017).","journal-title":"Oncoimmunology"},{"key":"722_CR144","doi-asserted-by":"publisher","first-page":"573920","DOI":"10.3389\/fimmu.2020.573920","volume":"11","author":"H Lu","year":"2020","unstructured":"Lu, H. et al. High abundance of intratumoral \u03b3\u03b4 T cells favors a better prognosis in head and neck squamous cell carcinoma: a bioinformatic analysis. Front. Immunol. 11, 573920 (2020).","journal-title":"Front. Immunol."},{"key":"722_CR145","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004880","volume":"10","author":"S Nguyen","year":"2022","unstructured":"Nguyen, S. et al. V\u03b42 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. J. Immunother. Cancer 10, e004880 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR146","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1158\/2326-6066.CIR-20-0817","volume":"9","author":"NA Gherardin","year":"2021","unstructured":"Gherardin, N. A. et al. \u03b3\u03b4 T cells in Merkel cell carcinomas have a proinflammatory profile prognostic of patient survival. Cancer Immunol. Res. 9, 612\u2013623 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"722_CR147","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s43018-022-00376-z","volume":"3","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. A local human V\u03b41 T cell population is associated with survival in nonsmall-cell lung cancer. Nat. Cancer 3, 696\u2013709 (2022).","journal-title":"Nat. Cancer"},{"key":"722_CR148","first-page":"81","volume":"28","author":"S Buccheri","year":"2014","unstructured":"Buccheri, S., Guggino, G., Caccamo, N., Li Donni, P. & Dieli, F. Efficacy and safety of \u03b3\u03b4T cell-based tumor immunotherapy: a meta-analysis. J. Biol. Regul. Homeost. Agents 28, 81\u201390 (2014).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"722_CR149","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","volume":"102","author":"M Wilhelm","year":"2003","unstructured":"Wilhelm, M. et al. \u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200\u2013206 (2003).","journal-title":"Blood"},{"key":"722_CR150","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli, F. et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450\u20137457 (2007).","journal-title":"Cancer Res."},{"key":"722_CR151","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","volume":"60","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075\u20131084 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"722_CR152","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00277-022-04930-8","volume":"101","author":"T Dong","year":"2022","unstructured":"Dong, T. et al. CD277 agonist enhances the immunogenicity of relapsed\/refractory acute myeloid leukemia towards V\u03b42+ T cell cytotoxicity. Ann. Hematol. 101, 2195\u20132208 (2022).","journal-title":"Ann. Hematol."},{"key":"722_CR153","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","volume":"74","author":"HH Oberg","year":"2014","unstructured":"Oberg, H. H. et al. Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 74, 1349\u20131360 (2014).","journal-title":"Cancer Res."},{"key":"722_CR154","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/2326-6066.CIR-20-0138","volume":"9","author":"I de Weerdt","year":"2021","unstructured":"de Weerdt, I. et al. A bispecific antibody antagonizes prosurvival CD40 signaling and promotes V\u03b39V\u03b42 T cell-mediated antitumor responses in human B-cell malignancies. Cancer Immunol. Res. 9, 50\u201361 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"722_CR155","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-20-4576","volume":"27","author":"I de Weerdt","year":"2021","unstructured":"de Weerdt, I. et al. A bispecific single-domain antibody boosts autologous V\u03b39V\u03b42-T cell responses toward CD1d in chronic lymphocytic leukemia. Clin. Cancer Res. 27, 1744\u20131755 (2021).","journal-title":"Clin. Cancer Res."},{"key":"722_CR156","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","volume":"35","author":"R Ganesan","year":"2021","unstructured":"Ganesan, R. et al. Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia 35, 2274\u20132284 (2021).","journal-title":"Leukemia"},{"key":"722_CR157","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375641","volume":"7","author":"RCG de Bruin","year":"2017","unstructured":"de Bruin, R. C. G. et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells. Oncoimmunology 7, e1375641 (2017).","journal-title":"Oncoimmunology"},{"key":"722_CR158","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003850","volume":"9","author":"E Van Diest","year":"2021","unstructured":"Van Diest, E. et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J. Immunother. Cancer 9, e003850 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR159","doi-asserted-by":"publisher","first-page":"83392","DOI":"10.18632\/oncotarget.13110","volume":"7","author":"CB Schiller","year":"2016","unstructured":"Schiller, C. B. et al. CD19-specific triplebody SPM-1 engages NK and \u03b3\u03b4 T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget 7, 83392\u201383408 (2016).","journal-title":"Oncotarget"},{"key":"722_CR160","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell. Mol. Immunol. 18, 427\u2013439 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"722_CR161","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"722_CR162","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"D S\u00e1nchez Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez Mart\u00ednez, D. et al. Generation and proof-of-concept for allogeneic CD123 CAR-delta one T (DOT) cells in acute myeloid leukemia. J. Immunother. Cancer 10, e005400 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR163","doi-asserted-by":"publisher","first-page":"21133","DOI":"10.1038\/s41598-021-00536-8","volume":"11","author":"LS Lamb","year":"2021","unstructured":"Lamb, L. S. et al. A combined treatment regimen of MGMT-modified \u03b3\u03b4 T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Sci. Rep. 11, 21133 (2021).","journal-title":"Sci. Rep."},{"key":"722_CR164","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 9, e833\u2013e843 (2022).","journal-title":"Lancet Haematol."},{"key":"722_CR165","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"722_CR166","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"722_CR167","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138, 11\u201322 (2021).","journal-title":"Blood"},{"key":"722_CR168","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","volume":"126","author":"M Rischer","year":"2004","unstructured":"Rischer, M. et al. Human \u03b3\u03b4 T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br. J. Haematol. 126, 583\u2013592 (2004).","journal-title":"Br. J. Haematol."},{"key":"722_CR169","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","volume":"21","author":"DC Deniger","year":"2013","unstructured":"Deniger, D. C. et al. Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol. Ther. 21, 638\u2013647 (2013).","journal-title":"Mol. Ther."},{"key":"722_CR170","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis, A. et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol. Ther. 26, 354\u2013365 (2018).","journal-title":"Mol. Ther."},{"key":"722_CR171","first-page":"79","volume":"11","author":"X Zhai","year":"2021","unstructured":"Zhai, X. et al. MUC1-Tn-targeting chimeric antigen receptor-modified V\u03b39V\u03b42 T cells with enhanced antigen-specific anti-tumor activity. Am. J. Cancer Res. 11, 79\u201391 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"722_CR172","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.omto.2020.04.013","volume":"17","author":"WX Ang","year":"2020","unstructured":"Ang, W. X. et al. Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts. Mol. Ther. Oncolytics 17, 421\u2013430 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"722_CR173","doi-asserted-by":"publisher","first-page":"863155","DOI":"10.3389\/fimmu.2022.863155","volume":"13","author":"GM Ferry","year":"2022","unstructured":"Ferry, G. M. et al. A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy. Front. Immunol. 13, 863155 (2022).","journal-title":"Front. Immunol."},{"key":"722_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","volume":"11","author":"KP Nishimoto","year":"2022","unstructured":"Nishimoto, K. P. et al. Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin. Transl. Immunol. 11, e1373 (2022).","journal-title":"Clin. Transl. Immunol."},{"issue":"Suppl. 16","key":"722_CR175","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 7509 (2022).","journal-title":"J. Clin. Oncol."},{"key":"722_CR176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003441","volume":"9","author":"A Makkouk","year":"2021","unstructured":"Makkouk, A. et al. Off-the-shelf V\u03b4 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J. Immunother. Cancer 9, e003441 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR177","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marcu-Malina","year":"2011","unstructured":"Marcu-Malina, V. et al. Redirecting \u03b1\u03b2T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor. Blood 118, 50\u201359 (2011).","journal-title":"Blood"},{"key":"722_CR178","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans, T. et al. GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR. Front. Immunol. 9, 1062 (2018).","journal-title":"Front. Immunol."},{"key":"722_CR179","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","volume":"7","author":"I Johanna","year":"2019","unstructured":"Johanna, I. et al. Evaluating in vivo efficacy\u2013toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. J. Immunother. Cancer 7, 69 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"722_CR180","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","volume":"4","author":"Y Xu","year":"2018","unstructured":"Xu, Y. et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. 4, 62 (2018).","journal-title":"Cell Discov."},{"key":"722_CR181","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1006\/clim.2000.4978","volume":"98","author":"L Nicolas","year":"2001","unstructured":"Nicolas, L. et al. Human \u03b3\u03b4 T cells express a higher TCR\/CD3 complex density than \u03b1\u03b2 T cells. Clin. Immunol. 98, 358\u2013363 (2001).","journal-title":"Clin. Immunol."},{"key":"722_CR182","doi-asserted-by":"publisher","first-page":"12068","DOI":"10.1038\/s41598-022-15946-5","volume":"12","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma. Sci. Rep. 12, 12068 (2022).","journal-title":"Sci. Rep."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00722-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T14:07:38Z","timestamp":1677074858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":182,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1038\/s41571-022-00722-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"8 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors receive funding from a sponsored research agreement with Takeda Development Center Americas, Inc, Lexington, MA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}